Skip to main content
OpenTrials
Completed

NCT Number: NCT03189511

Effect of Fluvastatin on Brown Fat Activity

The purpose of this study is to elucidate the effects of Fluvastatin on brown adipose tissue activity in humans.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

University Hospital of Zurich, PET/MR Center, Schlieren, Canton of Zurich, Switzerland

Loading trial locations.

About this study

Statins, inhibitors of cholesterol biosynthesis, act by inhibiting the enzyme of the mevalonate pathway. Although the clinical benefits of statins are undisputable, they have been shown to increase insulin resistance and incidence of type 2 diabetes mellitus, the mechanism of which is currently not clear.

The main function of brown adipose tissue (BAT) is non-shivering thermogenesis (i.e. heat production through energy dissipation) in brown adipocytes. There has been a growing interest in BAT as a novel therapeutic approach to increase energy expenditure in order to facilitate weight-loss and increase insulin sensitivity.

BAT activity will be assessed using calorimetric test and [18F]-Fluorodeoxyglucose (FDG) positron emission tomography (PET).

We speculate that statins inhibit BAT function and that this mechanism may contribute to the above mentioned increase in insulin resistance.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male volunteers (18-40 y)
  • body mass index 19 to 27 kg/m²
  • Fluent in German or English

Exclusion criteria

  • Regular physical exercise of more than >150 min of exercise per week.
  • Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
  • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.),
  • Clinically indicated intake of the following medications: Corticosteroids, CYP3A4-Inhibitors (Itraconazol, Voriconazol, Fluconazol, Clarithromycin, Erythromycin, Indinavir, Nelfinavir, Ritonavir, Grapefruit juice), Beta-Blocker, Neuroleptics, Tricyclic Antidepressants,
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present study,
  • Participation in another study involving ionizing radiation in the same year,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons,
  • MRI contraindications: Not MRI-compatible metal in the body, cardiac pacemaker, History of surgery with possible metal clips/parts still in the body, claustrophobia.
  • Resting pulse rate > 70 bpm
  • Known arterial hypertension or resting blood pressure > 130/80 mmHg.
  • frequence corrected QT-time (QTc) >430 ms
  • Serum creatinine > 1.5x upper limit of norm (ULN), i.e.> 145 µmol/L
  • creatine kinase > 1.5x ULN, i.e. > 300 U/L
  • aspartate transaminase (ASAT) > 1.5x ULN, i.e. > 51 U/L
  • alanine aminotransferase (ALAT) > 1.5x ULN, i.e. > 88 U/L
  • Hypothyroidism
  • Vitamin D deficiency, Vitamin D3 < 25 nmol/L
  • Intake of anticoagulants or inhibitors of platelet aggregation (e.g. Aspirin, clopidogrel).
  • Known tendency to form keloids (hypertrophic scar tissue)

Treatment and study plan

Fluvastatin

Drug

Fluvastatin 40 mg twice daily per mouth for 14 days.

Other names: Lescol

Primary outcomes

  1. (18)F-FDG uptake in the supraclavicular brown adipose tissue measured by PET by the maximum standardized uptake value (SUVmax)

    Time frame: 14 days

    Cold and Mirabegron induced 18F-FDG uptake into the supra-clavicular brown adipose tissue (scBAT) as determined by 18F-FDG PET/MR standardized uptake value (SUVmax) after two weeks of treatment with Fluvastatin.

Secondary outcomes

  1. The mean standardized uptake value for 18F-FDG uptake (SUVmean) in the supraclavicular adipose tissue depot

    Time frame: 14 days

    SUVmean in the supraclavicular adipose tissue depot (analog. SUVmax)

  2. Volume of supraclavicular BAT

    Time frame: 14 days

    Volume of supraclavicular BAT as determined on Magnetic Resonance Imaging (MRI)

  3. fat fraction with T2 relaxation time of the BAT depot

    Time frame: 14 days

    fat fraction with T2 relaxation time of the scBAT depot as determined by MRI

  4. Cold induced thermogenesis

    Time frame: 14 days

    Cold induced thermogenesis: Increase in energy expenditure above resting metabolic rate in response to a mild cold stimulus and pharmacologic stimulation with Mirabegron.

  5. Supraclavicular skin temperature in response to mild cold stimulus

    Time frame: 14 days

    Supraclavicular skin temperature in response to mild cold stimulus measured by local probe

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • University of Basel

Registry information

Official study title

Short Term Effect of Fluvastatin on Brown Adipose Tissue Thermogenesis and Activity in Humans

Acronym: FluvaBAT

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 16, 2017
Registry last updated
May 31, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.